Deborah Toppmeyer is an Oncology physician affiliated with Rutgers. OpenAlex indexes 162 publications with 9,940 citations (h-index 34); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
195 Little Albany St
New Brunswick, NJ 089011914
Telephone
732-235-2465Registry record last updated 5 Feb 2008.
Clinical trials
- Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Sponsor: Rutgers, The State University of New Jersey
- Internet Use Among Women With Recurrent Metastatic Breast Cancer
Sponsor: University of Medicine and Dentistry of New Jersey
- Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Sponsor: Rutgers, The State University of New Jersey
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20251 payment
- Daiichi Sankyo Inc.Program year20252 payments
- PFIZER INC.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
93.2%Aromatase Inhibitor64%Anastrozole56%Letrozole39%Exemestane5%Part D<11 patientsEstrogen Agonist/Antagonist18.5%Tamoxifen Citrate100%Part D≥27 patients+ 1 more class in this area
Nervous system
6.8%SSRI3.6%Sertraline Hcl100%Part D<11 patientsGabapentinoids3.3%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1999–2005 per NIH RePORTER. The latest:
- Phase II Doxorubicin/Vinorelbine in wtp53 Breast Cancer
Univ of Med/dent Nj-R W Johnson Med Sch
FY2005$268,397R01CA095275 - Phase II Doxorubicin/Vinorelbine in wtp53 Breast Cancer
Univ of Med/dent Nj-R W Johnson Med Sch
FY2004$268,397R01CA095275 - Phase II Doxorubicin/Vinorelbine in wtp53 Breast Cancer
Univ of Med/dent Nj-R W Johnson Med Sch
FY2003$255,060R01CA095275
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).
Journal of Clinical Oncology
2023 - Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
Frontiers in Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Sherine Gabriel, MD
Rutgers
Julius Gardin, MD
Rutgers
Abraham Aviv, MD
Rutgers
Partho Sengupta, MD, DM
Rutgers
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”